MedTrace Logo

Enstilar in Combination With Biologic Agents

NCT03080545 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-01-03

No results posted yet for this study

Summary

Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.

Conditions

Interventions

DRUG

Enstilar 0.005%-0.064% Topical Foam

Topical foam

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2017-10-30
Completion
2017-10-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03080545 on ClinicalTrials.gov